## An AI characterised functional ingredient derived from rice inhibits TNF-α and significantly improves physical strength in an inflammaging population

Kathy Kennedy<sup>1</sup>, Brian Keogh<sup>1</sup>, Cyril Lopez<sup>1</sup>, Alessandro Adelfio<sup>1</sup>, Brendan Molloy<sup>1</sup>, Alish Kerr<sup>1</sup>, Audrey M. Wall<sup>\*1</sup>, Ga d Jalowicki<sup>1</sup>, Th érèse A. Holton<sup>1</sup> and Nora Khaldi<sup>1</sup>

<sup>1</sup> Nuritas Ltd, Joshua Dawson House, Dawson St, Dublin 2, D02 RY95, Ireland.

Supplementary Materials

\*Corresponding Author Audrey Wall Email: wall.audrey@nuritas.com






Figure S1. Cell viability following rice NPN treatment. Percentage viability of Thp-1 cells with increasing concentrations of rice NPN. Data presented are the mean  $\pm$  SEM of at least 2 individual experiments carried out in at least triplicate.



**Figure S2: Ion spectra for predicted peptides detected in rice NPN.** Ion spectra are shown for peptides (a) pep\_ZBRXEN (b) pep\_6QEKFQ (c) pep\_H1REMR (d) pep\_7XU902 (e) pep\_35E7UW (f) pep\_CICEMV and (g) pep\_55AEE5D.



**Figure S3: Predicted peptide did not reduce LPS induced TNF-** $\alpha$  secretion. Treatment with constituent peptide, pep\_GQYHKK, did not reduce the secretion of TNF- $\alpha$  in THP-1 differentiated macrophages after treatment with LPS. THP-1 macrophages were treated with predicted peptide (0.5 - 5 µg/mL) for 24 hours before treating with 100 ng/mL of LPS for 24 hours. The secretion of TNF- $\alpha$  was quantified by ELISA. Data presented are the mean ± SEM of 1 independent experiment in triplicate (\*P <0.05 \*\*P <0.0

## Table S1 Subject Anthropometric Data

	All	Male	Female
Gender n (%)	40 (100%)	15 (37.5%)	25 (62.5%)
Age (years)	68.49 ±0.51	69.34 ±0.86	67.99 ±0.62
(Mean $\pm$ S.E.)			
Weight (Kg)	74.42 ±1.71	80.74 ±2.73	$71.2 \pm 1.79$
(Mean ±S.E.)			
Height (m)	1.67 ±0.01	1.73 ±0.01	1.63 ±0.01
(Mean ±S.E.)			
BMI (Kg/m <sup>2</sup> )	26.65 ±0.42	26.87 ±0.67	26.52 ±0.56
(Mean ±S.E.)			
Respiratory Rate	16.85 ±0.31	17.2 ±0.48	16.63 ±0.4
(Mean ±S.E.)			
Blood pressure			
(Mean ±S.E.)			
Diastolic	80.48 ±1.56	81.8 ± 3.2	$79.68 \pm 1.65$
Systolic	131.0 ±2.52	132.6 ±4.05	130.04 ±3.27
		Treatment	Placebo
Adverse events	Nausea and loose stool	3	0
	Indigestion	1	1
	Constipation	1	0
	Rash / Joint Pain	0	1
Serious Adverse Events		None	None




Figure S4: AUC change from baseline for (a) IL-1 $\beta$ , (b) IL-6 and (c) C-Reactive Protein.